This is so random, I was just reading his stuff in LTR this morning, specifically to see how applicable his analysis is to Cinovec. What differentiates EMH from LTR is the stage of development, offtake status, finance status, jurisdiction, cost curve position (lepidolite vs spodumene) and process chemistry.
I do agree with most of his analysis though.
Anatol's post:
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
17.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $35.26M | |||
| Open | High | Low | Value | Volume |
| 17.0¢ | 17.0¢ | 17.0¢ | $4.209K | 24.76K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 329698 | 17.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 17.5¢ | 5941 | 1 |
View Market Depth
| Last trade - 10.49am 20/06/2025 (20 minute delay) ? |
| EMH (ASX) Chart |